Beard et al. used enzyme-linked immunosorbent assays (ELISAs) to determine the circulating levels of hepsin in the serum for 424 patients with prostate cancer and found that the specificity was 89%, with a cut off >100 ng/mL determining hepsin positivity, in the active surveillance group. Here, HPN is linked to prostate cancer.